This coupled with diminished PGE2 signalling in lung fibrosis [25], and the strong inhibition of proliferation we observe with selective agonists suggests that EP2 &/or EP4 agonists are strong candidates for novel IPF treatments. Here, PTGER4 is linked to pulmonary fibrosis.